Current Report Filing (8-k)

   

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

October 13, 2016

Date of Report (Date of earliest event reported)

 

Flex Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware		001-36812		46-5087339
(State or other jurisdiction		(Commission File Number)		(IRS Employer Identification No.)
of incorporation)

 

800 Boylston Street, 24 th  Floor Boston, MA		02199
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code: [phone]

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

o                  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 8.01	Other Events.

On October 13, 2016, Flex Pharma, Inc. issued a press release providing a nocturnal leg cramp regulatory and clinical update. A copy of this press release is filed herewith as Exhibit 99.1 and the information contained therein is incorporated by reference into this Current Report on Form 8-K.

 

Item 9.01                                            Financial Statements and Exhibits.

 

(d)                                  Exhibits

 

Exhibit No.		Description
99.1		Press Release, dated October 13, 2016

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Flex Pharma, Inc.
Dated: October 13, 2016
	By:	/s/ Robert Hadfield
		Robert Hadfield
		General Counsel

---

INDEX TO EXHIBITS

 

Exhibit No.		Description
99.1		Press Release dated October 13, 2016